Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

EvaMobs

Financiado

Evolvable and rapidly adaptable monobodies: a broad-spectrum antiviral platform

With progress in globalization, expansion of human populations into natural habitats, and aggravation of climate change comes an increased risk of viral outbreaks. As demonstrated by the COVID-19 pandemic, not being prepared for s... ver más

31/12/2028

UNL

8M€

Presupuesto del proyecto: 8M€

Líder del proyecto

UNIVERSIDADE NOVA DE LISBOA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 11 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-11-23

HORIZON-HLTH-2023-DISEASE-03-04: Pandemic preparedness and response:... ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or...

I+D

Cerrada hace 1 año

0% 100%

11 Participantes

UNL

3.42M€ | Lider

INSTITUTE FOR MEDICAL RESEAR...

337.06K€ | Participante

EPFL

N.D. | Participante

UCP

630.73K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

NAVIPP New AntiVirals for Infections with Pandemic Potential 6M€ Cerrado

FLUIDITY Fighting Large-Scale Untreated Infectious Diseases with Inno... 5M€ Cerrado

VISION Virus Inhibition by siRNA Optimized by NMR 150K€ Cerrado

PDC2021-121255-I00 UNA NUEVA PLATAFORMA ANTIVIRAL BASADA EN ARN: PRUEBA DE CONC... 133K€ Cerrado

PID2021-126130OB-I00 LUCHA CONTRA LOS VIRUS: ESTUDIOS ESTRUCTURALES DE INTERACCIO... 260K€ Cerrado

Inhibicov Hit-to-Lead Development of potent broad-spectrum coronavirus... 150K€ Cerrado

Duración del proyecto: 61 meses Fecha Inicio: 2023-11-23
Fecha Fin: 2028-12-31

Líder del proyecto

UNIVERSIDADE NOVA DE LISBOA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 8M€

Descripción del proyecto With progress in globalization, expansion of human populations into natural habitats, and aggravation of climate change comes an increased risk of viral outbreaks. As demonstrated by the COVID-19 pandemic, not being prepared for such events has devastating consequences on public health, society and the economy. EvaMobs will improve preparedness of the European Union (EU) for the next viral outbreak(s) of pandemic potential by developing a platform for the discovery, development, production and validation of evolvable and rapidly adaptable antivirals. These innovative medicines will be based on small human-derived proteins called monobodies (Mobs). As Mobs can be engineered to have high binding affinity for virtually any viral protein, this platform can be easily adapted to a broad range of viruses, including newly emerging viruses and viral variants. To demonstrate the capacity of this platform it will first be applied to four pathogenic viruses with epidemic and/or pandemic potential: Influenza A, SARS-CoV-2, respiratory syncytial virus, and Zika virus. Deep-learning and computational design tools will allow generation of tailor-made Mobs with cryo-EM elucidating the molecular details of their binding interaction. Simple bacterial expression of Mobs, the development of a semi-automated high-throughput screening platform for evaluation of the Mobs’ stability and target affinity and streamlined in vitro and in vivo preclinical validation, will allow rapid development and selection of stable and potently neutralizing candidates. The Mob with the best preclinical indicators will then be tested in a phase I clinical trial after implementing a stable formulation and GMP production. The optimized platform can then be adapted to other viruses. Therefore, EvaMobs provides an innovative, robust and flexible platform for antiviral biologics development as well as a diverse portfolio of validated drugs, strengthening the EU’s pandemic preparedness.

Conecta tu I+D

Entra hoy

¿Olvide mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores